Danaher's Masimo Acquisition Raises Concerns Amid Stock Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2026
0mins
Source: Yahoo Finance
- Acquisition Impact: Danaher's $9.9 billion acquisition of Masimo is expected to boost adjusted EPS by $0.15 to $0.20 in the first year, yet it raises concerns over patent disputes with Apple and increased debt levels.
- Financial Performance: In Q1 2023, Danaher reported revenues of $5.95 billion, a 3% year-over-year increase, with EPS at $1.45, reflecting a 9.8% growth, demonstrating resilience amid challenges.
- Market Dynamics: The U.S. pharma and life sciences sector saw M&A activity exceed $65 billion in Q1 2026, nearly doubling the previous year's total, indicating large pharmaceutical companies are seeking acquisitions to enhance their pipelines, which could benefit Danaher's equipment sales.
- Future Outlook: Despite the execution risks of integrating Masimo, Danaher raised its 2026 EPS guidance to a range of $8.35 to $8.55, indicating confidence in future growth, although the market remains cautious about the stock's rebound potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 193.620
Low
240.00
Averages
266.18
High
310.00
Current: 193.620
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services. The Company also provides pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halper Sadeh LLC Investigates Danaher Corporation Executives' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether Danaher Corporation executives breached their fiduciary duties to shareholders, which could lead to corporate governance reforms and fund returns, thereby enhancing shareholder rights.
- Legal Fee Arrangement: The firm operates on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal expenses, a strategy designed to reduce the financial burden on shareholders and encourage participation in legal actions.
- Importance of Shareholder Participation: Involvement from shareholders can improve company policies and oversight mechanisms, enhancing transparency and accountability, which in turn boosts management efficiency and shareholder value, demonstrating the power of collective action.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing their expertise in protecting investor rights.
See More
Danaher Foundation Commits $1 Million to Combat Ebola Outbreak
- Emergency Funding Support: The Danaher Foundation has announced a $1 million commitment to support the Ebola outbreak response in the Democratic Republic of Congo and Uganda, aiming to rapidly address urgent needs through partnerships with Save the Children, the International Rescue Committee, and World Food Program USA.
- Collaborative Response Efforts: The funding will be distributed among the three organizations to enable flexible responses to critical needs such as infection prevention, hygiene support, and emergency food assistance, ensuring resources reach the most affected communities quickly as the situation evolves.
- Children's Health Crisis: According to the World Health Organization, over 1,000 cases of Ebola have been confirmed in the DRC, with children being particularly vulnerable and more than twice as likely to die after infection, highlighting the urgent need for access to basic healthcare and protection.
- Global Health Challenge: The outbreak has been declared a Public Health Emergency of International Concern by the WHO, reflecting the severe consequences of long-term underinvestment in health services and recent global funding cuts in a fragile humanitarian environment.
See More
Danaher Foundation Commits $1 Million to Combat Ebola Outbreak
- Emergency Funding Support: The Danaher Foundation has announced a $1 million commitment to support the Ebola outbreak response in the Democratic Republic of Congo and Uganda, aiming to rapidly address urgent needs through partnerships with Save the Children, the International Rescue Committee, and World Food Program USA.
- Collaborative Response Efforts: The funding will be distributed among the three organizations to enable flexible responses to critical needs such as infection prevention, hygiene support, and community health services, thereby directly saving lives and mitigating the impact of the outbreak.
- Children's Health Crisis: According to the World Health Organization, over 1,000 cases of Ebola have been confirmed in the DRC, with children being particularly vulnerable and more than twice as likely to die after infection, highlighting the urgent need for basic healthcare and protection.
- Global Health Challenge: The Ebola outbreak has been declared a Public Health Emergency of International Concern by the WHO, marking it as the largest known Bundibugyo virus outbreak in history, underscoring the severe consequences of global underinvestment in health services.
See More
Danaher Corporation Rated as Top Non-Tech Stock by Analysts
- FDA 510(k) Clearance: Masimo announced FDA 510(k) clearance for its Radius VSM® wearable continuous patient monitor, which now includes an opioid-induced respiratory depression detection capability that utilizes advanced pattern recognition to analyze continuous physiological data, enabling clinicians to identify early signs of respiratory compromise in patients receiving opioid therapy, thereby enhancing patient safety and monitoring efficiency.
- Analyst Rating Changes: Piper Sandler has initiated coverage of Danaher Corporation (DHR) while expressing caution regarding its future growth catalysts, noting that the current growth outlook is similar to past performance and that Thermo Fisher appears slightly cheaper on a P/E basis, indicating market divergence in expectations for Danaher's future performance.
- Market Positioning Analysis: Danaher’s design, manufacturing, and marketing of professional, medical, industrial, and commercial products and services position it as a significant diagnostics stock, although analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, reflecting a diverse perspective on investment opportunities in the current market.
- Investment Potential Assessment: While Danaher is viewed as a potentially strong investment, analysts express insufficient confidence in its future growth, suggesting that in the current market environment, some AI stocks may be more attractive, prompting investors to carefully consider the balance of risk and reward in their selections.
See More
Danaher's Masimo Acquisition Raises Concerns Amid Growth Potential
- Acquisition Potential: Danaher's $9.9 billion acquisition of Masimo raises patent dispute concerns but is expected to add $0.15 to $0.20 to adjusted EPS in the first year, scaling to $0.70 by year five, indicating significant future growth potential.
- First Quarter Recovery: In Q1, Danaher reported revenue of $5.95 billion, a 3% year-over-year increase, with EPS at $1.45, up 9.8%, demonstrating financial resilience despite a 22% stock price decline this year.
- Significant Order Growth: The company noted a 30% year-over-year increase in equipment orders, signaling the start of a multi-year manufacturing investment cycle, bolstered by reshoring trends and renewed interest in the life sciences sector.
- Low Market Valuation: Despite execution risks, Danaher's stock trades at just over 20 times forward earnings, significantly below its typical valuation over the past decade, suggesting that if management successfully integrates Masimo, the current stock price may be undervalued.
See More
Danaher's Masimo Acquisition Raises Concerns Amid Stock Decline
- Acquisition Impact: Danaher's $9.9 billion acquisition of Masimo is expected to boost adjusted EPS by $0.15 to $0.20 in the first year, yet it raises concerns over patent disputes with Apple and increased debt levels.
- Financial Performance: In Q1 2023, Danaher reported revenues of $5.95 billion, a 3% year-over-year increase, with EPS at $1.45, reflecting a 9.8% growth, demonstrating resilience amid challenges.
- Market Dynamics: The U.S. pharma and life sciences sector saw M&A activity exceed $65 billion in Q1 2026, nearly doubling the previous year's total, indicating large pharmaceutical companies are seeking acquisitions to enhance their pipelines, which could benefit Danaher's equipment sales.
- Future Outlook: Despite the execution risks of integrating Masimo, Danaher raised its 2026 EPS guidance to a range of $8.35 to $8.55, indicating confidence in future growth, although the market remains cautious about the stock's rebound potential.
See More
Halper Sadeh LLC Investigates Danaher Corporation Executives' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether Danaher Corporation executives breached their fiduciary duties to shareholders, which could lead to corporate governance reforms and fund returns, thereby enhancing shareholder rights.
- Legal Fee Arrangement: The firm operates on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal expenses, a strategy designed to reduce the financial burden on shareholders and encourage participation in legal actions.
- Importance of Shareholder Participation: Involvement from shareholders can improve company policies and oversight mechanisms, enhancing transparency and accountability, which in turn boosts management efficiency and shareholder value, demonstrating the power of collective action.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing their expertise in protecting investor rights.
See More
Danaher Foundation Commits $1 Million to Combat Ebola Outbreak
- Emergency Funding Support: The Danaher Foundation has announced a $1 million commitment to support the Ebola outbreak response in the Democratic Republic of Congo and Uganda, aiming to rapidly address urgent needs through partnerships with Save the Children, the International Rescue Committee, and World Food Program USA.
- Collaborative Response Efforts: The funding will be distributed among the three organizations to enable flexible responses to critical needs such as infection prevention, hygiene support, and emergency food assistance, ensuring resources reach the most affected communities quickly as the situation evolves.
- Children's Health Crisis: According to the World Health Organization, over 1,000 cases of Ebola have been confirmed in the DRC, with children being particularly vulnerable and more than twice as likely to die after infection, highlighting the urgent need for access to basic healthcare and protection.
- Global Health Challenge: The outbreak has been declared a Public Health Emergency of International Concern by the WHO, reflecting the severe consequences of long-term underinvestment in health services and recent global funding cuts in a fragile humanitarian environment.
See More
Danaher Foundation Commits $1 Million to Combat Ebola Outbreak
- Emergency Funding Support: The Danaher Foundation has announced a $1 million commitment to support the Ebola outbreak response in the Democratic Republic of Congo and Uganda, aiming to rapidly address urgent needs through partnerships with Save the Children, the International Rescue Committee, and World Food Program USA.
- Collaborative Response Efforts: The funding will be distributed among the three organizations to enable flexible responses to critical needs such as infection prevention, hygiene support, and community health services, thereby directly saving lives and mitigating the impact of the outbreak.
- Children's Health Crisis: According to the World Health Organization, over 1,000 cases of Ebola have been confirmed in the DRC, with children being particularly vulnerable and more than twice as likely to die after infection, highlighting the urgent need for basic healthcare and protection.
- Global Health Challenge: The Ebola outbreak has been declared a Public Health Emergency of International Concern by the WHO, marking it as the largest known Bundibugyo virus outbreak in history, underscoring the severe consequences of global underinvestment in health services.
See More
Danaher Corporation Rated as Top Non-Tech Stock by Analysts
- FDA 510(k) Clearance: Masimo announced FDA 510(k) clearance for its Radius VSM® wearable continuous patient monitor, which now includes an opioid-induced respiratory depression detection capability that utilizes advanced pattern recognition to analyze continuous physiological data, enabling clinicians to identify early signs of respiratory compromise in patients receiving opioid therapy, thereby enhancing patient safety and monitoring efficiency.
- Analyst Rating Changes: Piper Sandler has initiated coverage of Danaher Corporation (DHR) while expressing caution regarding its future growth catalysts, noting that the current growth outlook is similar to past performance and that Thermo Fisher appears slightly cheaper on a P/E basis, indicating market divergence in expectations for Danaher's future performance.
- Market Positioning Analysis: Danaher’s design, manufacturing, and marketing of professional, medical, industrial, and commercial products and services position it as a significant diagnostics stock, although analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, reflecting a diverse perspective on investment opportunities in the current market.
- Investment Potential Assessment: While Danaher is viewed as a potentially strong investment, analysts express insufficient confidence in its future growth, suggesting that in the current market environment, some AI stocks may be more attractive, prompting investors to carefully consider the balance of risk and reward in their selections.
See More
Danaher's Masimo Acquisition Raises Concerns Amid Growth Potential
- Acquisition Potential: Danaher's $9.9 billion acquisition of Masimo raises patent dispute concerns but is expected to add $0.15 to $0.20 to adjusted EPS in the first year, scaling to $0.70 by year five, indicating significant future growth potential.
- First Quarter Recovery: In Q1, Danaher reported revenue of $5.95 billion, a 3% year-over-year increase, with EPS at $1.45, up 9.8%, demonstrating financial resilience despite a 22% stock price decline this year.
- Significant Order Growth: The company noted a 30% year-over-year increase in equipment orders, signaling the start of a multi-year manufacturing investment cycle, bolstered by reshoring trends and renewed interest in the life sciences sector.
- Low Market Valuation: Despite execution risks, Danaher's stock trades at just over 20 times forward earnings, significantly below its typical valuation over the past decade, suggesting that if management successfully integrates Masimo, the current stock price may be undervalued.
See More
Danaher's Masimo Acquisition Raises Concerns Amid Stock Decline
- Acquisition Impact: Danaher's $9.9 billion acquisition of Masimo is expected to boost adjusted EPS by $0.15 to $0.20 in the first year, yet it raises concerns over patent disputes with Apple and increased debt levels.
- Financial Performance: In Q1 2023, Danaher reported revenues of $5.95 billion, a 3% year-over-year increase, with EPS at $1.45, reflecting a 9.8% growth, demonstrating resilience amid challenges.
- Market Dynamics: The U.S. pharma and life sciences sector saw M&A activity exceed $65 billion in Q1 2026, nearly doubling the previous year's total, indicating large pharmaceutical companies are seeking acquisitions to enhance their pipelines, which could benefit Danaher's equipment sales.
- Future Outlook: Despite the execution risks of integrating Masimo, Danaher raised its 2026 EPS guidance to a range of $8.35 to $8.55, indicating confidence in future growth, although the market remains cautious about the stock's rebound potential.
See More
